<DOC>
	<DOCNO>NCT00226408</DOCNO>
	<brief_summary>The study protocol conduct compare intermittent high-dose i.v . administation interferon alpha-2b standard high-dose treatment Kirkwood distant metastasis free survival ( DMFI ) primary endpoint .</brief_summary>
	<brief_title>Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon</brief_title>
	<detailed_description>Arm A : Interferon-alpha-2b 20 MIU/m2 4 week . 5 day week i.v follow 48 week treatment 3 x 10 MIU/m2 s.c Arm B : Interferon-alpha-2b 20 MIU/m2 4 week . 5 day week i.v repeat 3 time 12 treatment-free-weeks cycle Secondary endpoint : Improved overall survival rate , Assess side effect therapy treatment arm , Assess time spend sick leave , Assess number treatment-related day hospital , Assess overall performance status , Assess blood MX protein level</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histological documentet cutaneous malognant melanoma Stage IIIa , IIIb , IIIc ( AJCC 2002 ) R0 resection date back longer 56 day Performance status ( ECOG o1 ) Bone marrow funktion : White cell count &gt; 3000 cells/ul , platletts &gt; 100000 cells/ul , hemoglobin &gt; 10 g/dl Liver kidney funktion : Serum creatinin &lt; 1.5 time upper limit normal , AST ALT &lt; 2.5 time upper limit normal , Serum bilirubin &lt; 2 time upper limit normal Written inform consent Confirmed distant metastasis Choroid mucosal melanoma Pregnant lactate woman woman childbearing potential use reliable form contraception Active autoimmun disease patient history neuropsychiatric disease require hospitalization Severe medical condition u : Florid hepatitis Severe acute infection Myocardial infarction within past year , symptomatic angina pectoris Grade III IV congestive heart failure serious pulmonary disease HIVpositive patient AIDS define condition treatment another clinical drug trial within last 30 day A history hypersensitivity interferon alfa History maignant disease past 5 year ( except curatively treat skin carcinoma situ carcinoma ) Prior high dose interferon alfa therapy.Prior adjuvant low dose intermediatedose interferon alfa therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>melanoma , adjuvant therapy , stageIII Interferon</keyword>
	<keyword>high dose</keyword>
</DOC>